Ionis Pharmaceuticals

GSK ESMO
Biotech

GSK's 'functional cure' for hep B proves worth in ph. 3 trials

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of phase 3 studies, setting up the pharma for a push to the FDA.
James Waldron Jan 7, 2026 6:15am
Crossing crosswalk walking road

Ionis rare disease candidate ekes out phase 3 win

Sep 22, 2025 10:46am
patent infringement patent lawsuit

Arrowhead sues Ionis over patent dispute for Tryngolza rival

Sep 11, 2025 11:33am
RNA Concept 3D Render

RNA biotech emerges with $52M and clinical rare disease asset

Aug 25, 2025 10:13am
An artists 3D rendering of cancerous blood cells among healthy red blood cells The cells fill the image and are of various

Ono pays $280M upfront for Ionis' phase 2 blood cancer med

Mar 12, 2025 6:30am
photo of a royal flush laid out on the poker table with chips scattered nearby

Arrowhead posts phase 3 data ahead of market clash with Ionis

Sep 3, 2024 9:27am